{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:04:51Z","timestamp":1791932691645,"version":"4.3.4"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["70310"],"award-info":[{"award-number":["70310"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14830-5","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:49:30Z","timestamp":1758804570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The concurrent silencing of Tim-3 and STAT-3 promotes tumor regression both in vitro and in ovo"],"prefix":"10.1186","volume":"25","author":[{"given":"Reza","family":"Karami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Khodayari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Eshaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"KhodaKarami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bentolhoda","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Nikdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasti","family":"Moshtagh Mehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohid","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Jadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"1","key":"14830_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59\u201373.","journal-title":"Nat Rev Immunol"},{"key":"14830_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00245","volume":"9","author":"K Nurgali","year":"2018","unstructured":"Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?? Front Pharmacol. 2018;9: 245.","journal-title":"Front Pharmacol"},{"issue":"9","key":"14830_CR3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","volume":"22","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998\u20131009.","journal-title":"Curr Drug Targets"},{"key":"14830_CR4","doi-asserted-by":"publisher","first-page":"9605439","DOI":"10.1155\/2022\/9605439","volume":"2022","author":"D Kashyap","year":"2022","unstructured":"Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed research international. 2022;2022:9605439.","journal-title":"BioMed research international"},{"issue":"8","key":"14830_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"14830_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"4","key":"14830_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbae020","volume":"7","author":"M Yang","year":"2024","unstructured":"Yang M, Lin W, Huang J, Mannucci A, Luo H. Novel immunotherapeutic approaches in gastric cancer. Precis Clin Med. 2024;7(4): pbae020.","journal-title":"Precis Clin Med"},{"issue":"12","key":"14830_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/14728222.2024.2442437","volume":"28","author":"R Karami","year":"2024","unstructured":"Karami R, Fathi M, Jalali P, Hassannia H, Zarei A, Hojjat-Farsangi M, Jadidi F. The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy. Expert Opin Ther Targets. 2024;28(12):1093\u2013115.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"14830_CR9","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1038\/s41467-021-25865-0","volume":"12","author":"K Takamatsu","year":"2021","unstructured":"Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nat Commun. 2021;12(1):5547.","journal-title":"Nat Commun"},{"key":"14830_CR10","first-page":"403","volume-title":"Urologic Oncology: Seminars and Original Investigations: 2022","author":"K Attalla","year":"2022","unstructured":"Attalla K, Farkas AM, Anastos H, Audenet F, Galsky MD, Bhardwaj N, Sfakianos JP. TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. In: Urologic Oncology: Seminars and Original Investigations: 2022. Elsevier; 2022. p. 403\u20136."},{"issue":"3","key":"14830_CR11","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000528RR","volume":"35","author":"Z Chen","year":"2021","unstructured":"Chen Z, Dong D, Zhu Y, Pang N, Ding J. The role of Tim-3\/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. FASEB J. 2021;35(3): e21401.","journal-title":"FASEB J"},{"key":"14830_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.579351","volume":"11","author":"K Zang","year":"2021","unstructured":"Zang K, Hui L, Wang M, Huang Y, Zhu X, Yao B. TIM-3 as a prognostic marker and a potential immunotherapy target in human malignant tumors: a meta-analysis and bioinformatics validation. Front Oncol. 2021;11: 579351.","journal-title":"Front Oncol"},{"key":"14830_CR13","volume-title":"Listeria monocytogenes as a vector for cancer immunotherapies","author":"S Fernandez","year":"2024","unstructured":"Fernandez S. Listeria monocytogenes as a vector for cancer immunotherapies. University of California, Berkeley; 2024."},{"issue":"3","key":"14830_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.21037\/jtd-23-227","volume":"15","author":"C Zhang","year":"2023","unstructured":"Zhang C, Xu L, Ma Y, Huang Y, Zhou L, Le H, Chen Z. Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2023;15(3):1433.","journal-title":"J Thorac Dis"},{"issue":"12","key":"14830_CR15","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.4251\/wjgo.v15.i12.2138","volume":"15","author":"X-S Zhang","year":"2023","unstructured":"Zhang X-S, Zhou H-C, Wei P, Chen L, Ma W-H, Ding L, Liang S-C, Chen B-D. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4\u2009+\u2009and CD8\u2009+\u2009T cell-mediated antitumor immune responses. World J Gastrointest Oncol. 2023;15(12):2138.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"14830_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97\u2013111.","journal-title":"Immunol Rev"},{"issue":"7","key":"14830_CR17","first-page":"8018","volume":"8","author":"E Zhou","year":"2015","unstructured":"Zhou E, Huang Q, Wang J, Fang C, Yang L, Zhu M, Chen J, Chen L, Dong M. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol. 2015;8(7):8018\u201327.","journal-title":"Int J Clin Exp Pathol"},{"key":"14830_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101686","author":"C Chen","year":"2024","unstructured":"Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H, Ma S, Peng X, Sheng X, Sun Y. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8\u2009+\u2009T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101686.","journal-title":"Cell Rep Med"},{"key":"14830_CR19","volume-title":"Biochemical Regulation of the Tim-3-Galectin-9 Immunosuppressive Pathway under Normal Conditions and upon Cell Malignant Transformation","author":"ATH Seln\u00f8","year":"2021","unstructured":"Seln\u00f8 ATH. Biochemical Regulation of the Tim-3-Galectin-9 Immunosuppressive Pathway under Normal Conditions and upon Cell Malignant Transformation. University of Kent (United Kingdom); 2021."},{"issue":"4","key":"14830_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-4.18975","volume":"46","author":"S Jafarkhani","year":"2024","unstructured":"Jafarkhani S, Hossein-Nataj H, Eslami-Jouybari M, Ghoreishi M, Asgarian-Omran H. PD-1 and TIM-3 blocking cannot enhance apoptosis of chronic lymphocytic leukemia cells induced by peripheral blood CD8\u2009+\u2009T cells. Exp Oncol. 2024;46(4):287\u201394.","journal-title":"Exp Oncol"},{"issue":"18","key":"14830_CR21","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41388-018-0140-4","volume":"37","author":"H Zhang","year":"2018","unstructured":"Zhang H, Song Y, Yang H, Liu Z, Gao L, Liang X, Ma C. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-\u03baB\/IL-6\/STAT3 axis. Oncogene. 2018;37(18):2456\u201368.","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"14830_CR22","first-page":"i13","volume":"25","author":"I Ausejo-Mauleon","year":"2023","unstructured":"Ausejo-Mauleon I, Laspidea V, de la Nava D, Nuin S, Palacios-Alonso D, Marco-Sanz J, Becher O, Jiang L, Filbon MG, Pastor F. DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS. Neurooncology. 2023;25(Suppl 1):i13.","journal-title":"Neurooncology"},{"issue":"11","key":"14830_CR23","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","volume":"41","author":"I Ausejo-Mauleon","year":"2023","unstructured":"Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrod\u00e1n L, Garc\u00eda-Moure M, Gonzalez-Huarriz M, Herv\u00e1s-Corpi\u00f3n I, Dhandapani L. TIM-3 Blockade in diffuse intrinsic Pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell. 2023;41(11):1911\u201326. e1918.","journal-title":"Cancer Cell"},{"key":"14830_CR24","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202130","author":"Y Cong","year":"2020","unstructured":"Cong Y, Wang X, Wang S, Qiao G, Li Y, Cao J, Jiang W, Cui Y. Tim-3 promotes tube formation and decreases tight junction formation in vascular endothelial cells. Biosci Rep. 2020. https:\/\/doi.org\/10.1042\/BSR20202130.","journal-title":"Biosci Rep"},{"issue":"5","key":"14830_CR25","first-page":"564","volume":"32","author":"Y Cong","year":"2020","unstructured":"Cong Y, Cui Y, Zhu S, Cao J, Zou H, Martin TA, Qiao G, Jiang W, Yu Z. Tim-3 promotes cell aggressiveness and Paclitaxel resistance through NF-\u03baB\/STAT3 signalling pathway in breast cancer cells. Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu. 2020;32(5):564\u201379.","journal-title":"Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu"},{"issue":"5","key":"14830_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.37349\/etat.2024.00202","volume":"5","author":"Z Hamel","year":"2024","unstructured":"Hamel Z, Sanchez S, Standing D, Anant S. Role of STAT3 in pancreatic cancer. Explor Target Anti-tumor Therapy. 2024;5(5):20.","journal-title":"Explor Target Anti-tumor Therapy"},{"key":"14830_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091280","author":"C R\u00e9b\u00e9","year":"2019","unstructured":"R\u00e9b\u00e9 C, Ghiringhelli F. STAT3, a master regulator of anti-tumor immune response. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091280.","journal-title":"Cancers (Basel)"},{"key":"14830_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","volume":"415","author":"Y Wang","year":"2018","unstructured":"Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 2018;415:117\u201328.","journal-title":"Cancer Lett"},{"issue":"11","key":"14830_CR29","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ijc.29923","volume":"138","author":"K Banerjee","year":"2016","unstructured":"Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570\u20138.","journal-title":"Int J Cancer"},{"issue":"10","key":"14830_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140694","volume":"10","author":"B Tomkowicz","year":"2015","unstructured":"Tomkowicz B, Walsh E, Cotty A, Verona R, Sabins N, Kaplan F, Santulli-Marotto S, Chin CN, Mooney J, Lingham RB, et al. TIM-3 Suppresses Anti-CD3\/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS One. 2015;10(10): e0140694.","journal-title":"PLoS One"},{"issue":"19","key":"14830_CR31","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, Smithgall TE, Kuchroo VK, Kane LP. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963\u201374.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"14830_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-018-0667-4","volume":"11","author":"F Liu","year":"2018","unstructured":"Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol. 2018;11(1):126.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14830_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","volume":"21","author":"G He","year":"2011","unstructured":"He G, Karin M. NF-\u03baB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21(1):159\u201368.","journal-title":"Cell Res"},{"key":"14830_CR34","doi-asserted-by":"publisher","first-page":"654749","DOI":"10.3389\/fimmu.2021.654749","volume":"12","author":"L Huang","year":"2021","unstructured":"Huang L, Xu Y, Fang J, Liu W, Chen J, Liu Z, Xu Q. Targeting STAT3 abrogates Tim-3 upregulation of adaptive resistance to PD-1 blockade on regulatory T cells of melanoma. Front Immunol. 2021;12:654749.","journal-title":"Front Immunol"},{"issue":"5","key":"14830_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41419-023-05848-3","volume":"14","author":"M Mishra","year":"2023","unstructured":"Mishra M, Yadav M, Kumar S, Kumar R, Sen P. TIM-3 increases the abundance of type-2 dendritic cells during leishmania donovani infection by enhancing IL-10 production via STAT3. Cell Death Dis. 2023;14(5):331.","journal-title":"Cell Death Dis"},{"issue":"4","key":"14830_CR36","doi-asserted-by":"publisher","first-page":"e1011329","DOI":"10.1371\/journal.ppat.1011329","volume":"19","author":"H Qi","year":"2023","unstructured":"Qi H, Li Y, Liu X, Jiang Y, Li Z, Xu X, Zhang H, Hu X. Tim-3 regulates the immunosuppressive function of decidual MDSCs via the Fyn-STAT3-C\/EBP\u03b2 pathway during Toxoplasma gondii infection. PLoS Pathog. 2023;19(4):e1011329.","journal-title":"PLoS Pathog"},{"key":"14830_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.117263","volume":"239","author":"N Ebrahimi","year":"2023","unstructured":"Ebrahimi N, Manavi MS, Nazari A, Momayezi A, Faghihkhorasani F, Abdulwahid A-HRR, Rezaei-Tazangi F, Kavei M, Rezaei R, Mobarak H. Nano-scale delivery systems for siRNA delivery in cancer therapy: new era of gene therapy empowered by nanotechnology. Environ Res. 2023;239: 117263.","journal-title":"Environ Res"},{"issue":"5","key":"14830_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic sirna: state-of-the-art and future perspectives. BioDrugs. 2022;36(5):549\u201371.","journal-title":"BioDrugs"},{"issue":"1","key":"14830_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B, Yang L. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025;10(1):73.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"14830_CR40","volume":"18","author":"A Kumari","year":"2023","unstructured":"Kumari A, Kaur A, Aggarwal G. The emerging potential of siRNA nanotherapeutics in treatment of arthritis. Asian J Pharm Sci. 2023;18(5): 100845.","journal-title":"Asian J Pharm Sci"},{"issue":"12","key":"14830_CR41","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/bioengineering11121308","volume":"11","author":"SG Lopez","year":"2024","unstructured":"Lopez SG, Estroff LA, Bonassar LJ. SiRNA treatment enhances collagen fiber formation in tissue-engineered meniscus via transient inhibition of aggrecan production. Bioengineering. 2024;11(12):1308.","journal-title":"Bioengineering"},{"key":"14830_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100103","volume":"3","author":"K Kumar","year":"2022","unstructured":"Kumar K, Rani V, Mishra M, Chawla R. New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy. Curr Res Pharmacol Drug Discov. 2022;3: 100103.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"1","key":"14830_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnol. 2023;21(1):381.","journal-title":"J Nanobiotechnol"},{"key":"14830_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100299","volume":"15","author":"F Wang","year":"2022","unstructured":"Wang F, Liu LS, Li P, Lau CH, Leung HM, Chin YR, Tin C, Lo PK. Cellular uptake, tissue penetration, biodistribution, and biosafety of threose nucleic acids: assessing in vitro and in vivo delivery. Mater Today Bio. 2022;15: 100299.","journal-title":"Mater Today Bio"},{"issue":"5","key":"14830_CR45","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1021\/acsami.1c23708","volume":"14","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang M, Zhou M, Zhang T, Gao Y, Li S, Lin Y, Cai X. Tetrahedral-framework nucleic acids carry small interfering RNA to downregulate toll-like receptor 2 gene expression for the treatment of sepsis. ACS Appl Mater Interfaces. 2022;14(5):6442\u201352.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"14830_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/genes13020319","volume":"13","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi Y, Tian S, Ui-Tei K. The siRNA off-target effect is determined by base-pairing stabilities of two different regions with opposite effects. Genes. 2022;13(2):319.","journal-title":"Genes"},{"key":"14830_CR47","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S497510","author":"Y Li","year":"2025","unstructured":"Li Y, Sun H, Cao D, Guo Y, Wu D, Yang M, Wang H, Shao X, Li Y, Liang Y. Overcoming biological barriers in cancer therapy: cell membrane-based nanocarrier strategies for precision delivery. Int J Nanomedicine. 2025. https:\/\/doi.org\/10.2147\/IJN.S497510.","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"14830_CR48","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.3390\/pharmaceutics14112463","volume":"14","author":"A Ahmad","year":"2022","unstructured":"Ahmad A, Imran M, Sharma N. Precision nanotoxicology in drug development: current trends and challenges in safety and toxicity implications of customized multifunctional nanocarriers for drug-delivery applications. Pharmaceutics. 2022;14(11):2463.","journal-title":"Pharmaceutics"},{"issue":"3","key":"14830_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbae017","volume":"7","author":"EM Jacob","year":"2024","unstructured":"Jacob EM, Huang J, Chen M. Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology. Precis Clin Med. 2024;7(3): pbae017.","journal-title":"Precis Clin Med"},{"key":"14830_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25112692","author":"F Mainini","year":"2020","unstructured":"Mainini F, Eccles MR. Lipid and polymer-based nanoparticle SiRNA delivery systems for cancer therapy. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25112692.","journal-title":"Molecules"},{"key":"14830_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/B978-0-443-14088-4.00007-1","volume-title":"Fundamentals and Biomedical Applications of Chitosan Nanoparticles","author":"B Acharya","year":"2025","unstructured":"Acharya B, Behera A, Deshmukh K, Moharana S. Biocompatibility, biodegradability, and toxicity evaluations of chitosan nanoparticles. In: Fundamentals and Biomedical Applications of Chitosan Nanoparticles. edn.: Elsevier; 2025. p. 139\u201387."},{"issue":"6","key":"14830_CR52","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1021\/acsabm.3c00984","volume":"7","author":"P Patra","year":"2024","unstructured":"Patra P, Upadhyay TK, Alshammari N, Saeed M, Kesari KK. Alginate-chitosan biodegradable and biocompatible based hydrogel for breast cancer immunotherapy and diagnosis: a comprehensive review. ACS Appl Bio Mater. 2024;7(6):3515\u201334.","journal-title":"ACS Appl Bio Mater"},{"key":"14830_CR53","volume-title":"Nanoclay-Recent Advances, New Perspectives and Applications","author":"S Yalcin","year":"2022","unstructured":"Yalcin S, Cankaya N. Chitosan-based nanocomposites for biological applications. In: Nanoclay-Recent Advances, New Perspectives and Applications. IntechOpen; 2022. edn."},{"key":"14830_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.121926","volume":"333","author":"K Ahmad","year":"2024","unstructured":"Ahmad K, Zhang Y, Chen P, Yang X, Hou H. Chitosan interaction with stomach mucin layer to enhances gastric retention and mucoadhesive properties. Carbohydr Polym. 2024;333: 121926.","journal-title":"Carbohydr Polym"},{"key":"14830_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.reactfunctpolym.2023.105634","volume":"191","author":"A Harugade","year":"2023","unstructured":"Harugade A, Sherje AP, Pethe A. Chitosan: a review on properties, biological activities and recent progress in biomedical applications. React Funct Polym. 2023;191: 105634.","journal-title":"React Funct Polym"},{"issue":"1","key":"14830_CR56","doi-asserted-by":"publisher","first-page":"17343","DOI":"10.1038\/s41598-023-44178-4","volume":"13","author":"A Pratap-Singh","year":"2023","unstructured":"Pratap-Singh A, Guo Y, Baldelli A, Singh A. Mercaptonicotinic acid activated thiolated chitosan (MNA-TG-chitosan) to enable peptide oral delivery by opening cell tight junctions and enhancing transepithelial transport. Sci Rep. 2023;13(1):17343.","journal-title":"Sci Rep"},{"issue":"7","key":"14830_CR57","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/pharmaceutics16070868","volume":"16","author":"V Antoniou","year":"2024","unstructured":"Antoniou V, Mourelatou EA, Galatou E, Avgoustakis K, Hatziantoniou S. Gene therapy with chitosan nanoparticles: modern formulation strategies for enhancing cancer cell transfection. Pharmaceutics. 2024;16(7):868.","journal-title":"Pharmaceutics"},{"issue":"10","key":"14830_CR58","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/pharmaceutics13101686","volume":"13","author":"N Aibani","year":"2021","unstructured":"Aibani N, Rai R, Patel P, Cuddihy G, Wasan EK. Chitosan nanoparticles at the biological interface: implications for drug delivery. Pharmaceutics. 2021;13(10):1686.","journal-title":"Pharmaceutics"},{"key":"14830_CR59","first-page":"174","volume":"41","author":"Z Huang","year":"2024","unstructured":"Huang Z, Zhang D, Tong L, Gao F, Zhang S, Wang X, Xie Y, Chen F, Liu C. Protonated-chitosan sponge with procoagulation activity for hemostasis in coagulopathy. Bioact Mater. 2024;41:174\u201392.","journal-title":"Bioact Mater"},{"issue":"2","key":"14830_CR60","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/molecules27020473","volume":"27","author":"C Yee Kuen","year":"2022","unstructured":"Yee Kuen C, Masarudin MJ. Chitosan nanoparticle-based system: a new insight into the promising controlled release system for lung cancer treatment. Molecules. 2022;27(2):473.","journal-title":"Molecules"},{"issue":"13","key":"14830_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/polym15132928","volume":"15","author":"T Virmani","year":"2023","unstructured":"Virmani T, Kumar G, Sharma A, Pathak K, Akhtar MS, Afzal O, Altamimi AS. Amelioration of cancer employing chitosan, its derivatives, and chitosan-based nanoparticles: recent updates. Polymers. 2023;15(13): 2928.","journal-title":"Polymers"},{"issue":"2","key":"14830_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/ph17020169","volume":"17","author":"IN Khan","year":"2024","unstructured":"Khan IN, Navaid S, Waqar W, Hussein D, Ullah N, Khan MUA, Hussain Z, Javed A. Chitosan-based polymeric nanoparticles as an efficient gene delivery system to cross blood brain barrier: in vitro and in vivo evaluations. Pharmaceuticals. 2024;17(2):169.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"14830_CR63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/polym17050558","volume":"17","author":"MG Dabija","year":"2025","unstructured":"Dabija MG, Olaru I, Ciuhodaru T, Stefanache A, Mihai C, Lungu II, Calin G, Stadoleanu C, Damir DL. Chitosan as a plurivalent biopolymer in nanodelivery systems. Polymers. 2025;17(5):558.","journal-title":"Polymers"},{"issue":"10","key":"14830_CR64","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/08853282241243010","volume":"38","author":"MT Isa","year":"2024","unstructured":"Isa MT, Abdulkarim AY, Bello A, Bello TK, Adamu Y. Synthesis and characterization of chitosan for medical applications: a review. J Biomater Appl. 2024;38(10):1036\u201357.","journal-title":"J Biomater Appl"},{"issue":"7","key":"14830_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/gels8070393","volume":"8","author":"A Pellis","year":"2022","unstructured":"Pellis A, Guebitz GM, Nyanhongo GS. Chitosan: sources, processing and modification techniques. Gels. 2022;8(7):393.","journal-title":"Gels"},{"key":"14830_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118050","volume":"264","author":"X Li","year":"2021","unstructured":"Li X, Xing R, Xu C, Liu S, Qin Y, Li K, Yu H, Li P. Immunostimulatory effect of chitosan and quaternary chitosan: a review of potential vaccine adjuvants. Carbohydr Polym. 2021;264: 118050.","journal-title":"Carbohydr Polym"},{"issue":"12","key":"14830_CR67","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.3390\/molecules26123694","volume":"26","author":"LG Confederat","year":"2021","unstructured":"Confederat LG, Tuchilus CG, Dragan M, Sha\u2019at M, Dragostin OM. Preparation and antimicrobial activity of chitosan and its derivatives: a concise review. Molecules. 2021;26(12):3694.","journal-title":"Molecules"},{"issue":"1","key":"14830_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/md20010069","volume":"20","author":"D Yu","year":"2022","unstructured":"Yu D, Feng J, You H, Zhou S, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. The microstructure, antibacterial and antitumor activities of chitosan oligosaccharides and derivatives. Mar Drugs. 2022;20(1): 69.","journal-title":"Mar Drugs"},{"issue":"1","key":"14830_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0378-5173(02)00548-3","volume":"250","author":"Y Xu","year":"2003","unstructured":"Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm. 2003;250(1):215\u201326.","journal-title":"Int J Pharm"},{"issue":"5","key":"14830_CR70","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/iub.2461","volume":"73","author":"M Fathi","year":"2021","unstructured":"Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpisheh V, Jalili A, Jadidi-Niaragh F. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life. 2021;73(5):726\u201338.","journal-title":"IUBMB Life"},{"issue":"10","key":"14830_CR71","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187\u201394.","journal-title":"J Exp Med"},{"key":"14830_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.723238","volume":"11","author":"Y Cong","year":"2021","unstructured":"Cong Y, Liu J, Chen G, Qiao G. The emerging role of T-cell Immunoglobulin Mucin-3 in breast cancer: a promising target for immunotherapy. Front Oncol. 2021;11: 723238.","journal-title":"Front Oncol"},{"key":"14830_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731175","volume":"11","author":"T Tian","year":"2021","unstructured":"Tian T, Li Z. Targeting Tim-3 in cancer with resistance to PD-1\/PD-L1 blockade. Front Oncol. 2021;11: 731175.","journal-title":"Front Oncol"},{"key":"14830_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119369","volume":"275","author":"N Joshi","year":"2021","unstructured":"Joshi N, Hajizadeh F, Dezfouli EA, Zekiy AO, Afjadi MN, Mousavi SM, Hojjat-Farsangi M, Karpisheh V, Mahmoodpoor A, Hassannia H. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sci. 2021;275: 119369.","journal-title":"Life Sci"},{"issue":"15","key":"14830_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202005155","volume":"33","author":"P Liang","year":"2021","unstructured":"Liang P, Ballou B, Lv X, Si W, Bruchez MP, Huang W, Dong X. Monotherapy and combination therapy using anti-angiogenic nanoagents to fight cancer. Adv Mater. 2021;33(15): 2005155.","journal-title":"Adv Mater"},{"key":"14830_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2016.12.012","volume":"246","author":"F Jadidi-Niaragh","year":"2017","unstructured":"Jadidi-Niaragh F, Atyabi F, Rastegari A, Kheshtchin N, Arab S, Hassannia H, Ajami M, Mirsanei Z, Habibi S, Masoumi F, et al. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J Control Release. 2017;246:46\u201359.","journal-title":"J Control Release"},{"issue":"6","key":"14830_CR77","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1007\/s13277-015-4732-0","volume":"37","author":"F Jadidi-Niaragh","year":"2016","unstructured":"Jadidi-Niaragh F, Atyabi F, Rastegari A, Mollarazi E, Kiani M, Razavi A, Yousefi M, Kheshtchin N, Hassannia H, Hadjati J, et al. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumor Biol. 2016;37(6):8403\u201312.","journal-title":"Tumor Biol"},{"key":"14830_CR78","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijbiomac.2020.01.273","volume":"149","author":"A Masjedi","year":"2020","unstructured":"Masjedi A, Ahmadi A, Atyabi F, Farhadi S, Irandoust M, Khazaei-Poul Y, Ghasemi Chaleshtari M, Edalati Fathabad M, Baghaei M, Haghnavaz N, et al. Silencing of IL-6 and STAT3 by SiRNA loaded hyaluronate-N,N,N-trimethyl Chitosan nanoparticles potently reduces cancer cell progression. Int J Biol Macromol. 2020;149:487\u2013500.","journal-title":"Int J Biol Macromol"},{"key":"14830_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.610303","volume":"11","author":"V Salemme","year":"2021","unstructured":"Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol. 2021;11: 610303.","journal-title":"Front Oncol"},{"key":"14830_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107933","volume":"99","author":"L Zhao","year":"2021","unstructured":"Zhao L, Cheng S, Fan L, Zhang B, Xu S. TIM-3: an update on immunotherapy. Int Immunopharmacol. 2021;99: 107933.","journal-title":"Int Immunopharmacol"},{"key":"14830_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01288","volume":"10","author":"S Qin","year":"2020","unstructured":"Qin S, Dong B, Yi M, Chu Q, Wu K. Prognostic values of TIM-3 expression in patients with solid tumors: a meta-analysis and database evaluation. Front Oncol. 2020;10: 1288.","journal-title":"Front Oncol"},{"issue":"8","key":"14830_CR82","first-page":"3419","volume":"8","author":"P Shen","year":"2016","unstructured":"Shen P, Yue R, Tang J, Si H, Shen L, Guo C, Zhang L, Han H, Song HK, Zhao P, et al. Preferential Tim-3 expression on Treg and CD8(+) T cells, supported by tumor-associated macrophages, is associated with worse prognosis in gastric cancer. Am J Translational Res. 2016;8(8):3419\u201328.","journal-title":"Am J Translational Res"},{"key":"14830_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010071","author":"V Sasidharan Nair","year":"2020","unstructured":"Sasidharan Nair V, Toor SM, Taha RZ, Ahmed AA, Kurer MA, Murshed K, Soofi ME, Ouararhni K, Alajez NM, Abu Nada M, et al. Transcriptomic profiling of tumor-infiltrating CD4(+)TIM-3(+) T cells reveals their suppressive, exhausted, and metastatic characteristics in colorectal cancer patients. Vaccines. 2020. https:\/\/doi.org\/10.3390\/vaccines8010071.","journal-title":"Vaccines"},{"key":"14830_CR84","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3389\/fimmu.2019.01594","volume":"10","author":"IM Yasinska","year":"2019","unstructured":"Yasinska IM, Sakhnevych SS, Pavlova L, Teo Hansen Seln\u00f8 A, Teuscher Abeleira AM, Benlaouer O, Gon\u00e7alves Silva I, Mosimann M, Varani L, Bardelli M, et al. The Tim-3-Galectin-9 pathway and its regulatory mechanisms in human breast cancer. Front Immunol. 2019;10:1594.","journal-title":"Front Immunol"},{"issue":"1","key":"14830_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02810-z","volume":"20","author":"B Mollavelioglu","year":"2022","unstructured":"Mollavelioglu B, Cetin Aktas E, Cabioglu N, Abbasov A, Onder S, Emiroglu S, T\u00fckenmez M, Muslumanoglu M, Igci A, Deniz G, et al. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. World J Surg Oncol. 2022;20(1): 349.","journal-title":"World J Surg Oncol"},{"key":"14830_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030645","author":"W Du","year":"2017","unstructured":"Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. TIM-3 as a target for cancer immunotherapy and mechanisms of action. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18030645.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"14830_CR87","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1007\/s11010-021-04156-8","volume":"476","author":"G Chalikonda","year":"2021","unstructured":"Chalikonda G, Lee H, Sheik A, Huh YS. Targeting key transcriptional factor STAT3 in colorectal cancer. Mol Cell Biochem. 2021;476(9):3219\u201328.","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"14830_CR88","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/cancers16061092","volume":"16","author":"V Krajka-Ku\u017aniak","year":"2024","unstructured":"Krajka-Ku\u017aniak V, Belka M, Papierska K. Targeting STAT3 and NF-\u03baB signaling pathways in cancer prevention and treatment: the role of chalcones. Cancers (Basel). 2024;16(6):1092.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"14830_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27227825","volume":"27","author":"R Alaaeldin","year":"2022","unstructured":"Alaaeldin R, Ali FE, Bekhit AA, Zhao Q-L, Fathy M. Inhibition of NF-kB\/IL-6\/JAK2\/STAT3 pathway and epithelial-mesenchymal transition in breast cancer cells by Azilsartan. Molecules. 2022;27(22): 7825.","journal-title":"Molecules"},{"key":"14830_CR90","doi-asserted-by":"publisher","first-page":"110041","DOI":"10.1016\/j.intimp.2023.110041","volume":"118","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Zhou Y, Huang Z, Wang M, Jiang J, Yan M, Xiang W, Li S, Yu Y, Chen L. Notopterol improves cognitive dysfunction and depression-like behavior via inhibiting STAT3\/NF-\u0138B pathway mediated inflammation in glioma-bearing mice. Int Immunopharmacol. 2023;118:110041.","journal-title":"Int Immunopharmacol"},{"key":"14830_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116458","volume":"233","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Anaraki KT, Motahhary M, Khalilipouya E, Nashtifani AH, Shafiei S, Farani MR. STAT3 as a newly emerging target in colorectal cancer therapy: tumorigenesis, therapy response, and pharmacological\/nanoplatform strategies. Environ Res. 2023;233: 116458.","journal-title":"Environ Res"},{"issue":"5","key":"14830_CR92","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41419-021-03773-x","volume":"12","author":"J Zhao","year":"2021","unstructured":"Zhao J, Wang X, Mi Z, Jiang X, Sun L, Zheng B, Wang J, Meng M, Zhang L, Wang Z. STAT3\/miR-135b\/NF-\u03baB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer. Cell Death Dis. 2021;12(5):493.","journal-title":"Cell Death Dis"},{"issue":"1","key":"14830_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12672-024-01698-3","volume":"16","author":"W Tie","year":"2025","unstructured":"Tie W, Ma T, Liu J, Yi Z, Xiong H, Bai J, Li Y, Li L, Zhang L. Visfatin promotes multiple myeloma cell proliferation and inhibits apoptosis by inducing IL-6 production via NF-\u03baB pathways. Discov Oncol. 2025;16(1):1\u201315.","journal-title":"Discov Oncol"},{"issue":"10","key":"14830_CR94","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1007\/s11033-023-08671-3","volume":"50","author":"P Mao","year":"2023","unstructured":"Mao P, Wang T, Du C-W, Yu X, Wang M-D. CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT\/NF-\u03bab signaling pathways. Mol Biol Rep. 2023;50(10):8015\u201323.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"14830_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.335","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Hu B, Sun YF, Huang XW, Cheng JW, Huang A, Zeng HY, Qiu SJ, Cao Y, Fan J. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF\/JAK1\/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021;11(2): e335.","journal-title":"Clin Transl Med"},{"issue":"1","key":"14830_CR96","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s40001-024-02168-w","volume":"29","author":"A Bahrami","year":"2024","unstructured":"Bahrami A, Khalaji A, Bahri Najafi M, Sadati S, Raisi A, Abolhassani A, Eshraghi R, Khaksary Mahabady M, Rahimian N, Mirzaei H. NF-\u03baB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets. Eur J Med Res. 2024;29(1):610.","journal-title":"Eur J Med Res"},{"key":"14830_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.866014","volume":"12","author":"SG Manore","year":"2022","unstructured":"Manore SG, Doheny DL, Wong GL, Lo H-W. IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment. Front Oncol. 2022;12: 866014.","journal-title":"Front Oncol"},{"issue":"4","key":"14830_CR98","doi-asserted-by":"publisher","first-page":"353","DOI":"10.54817\/IC.v63n4a03","volume":"63","author":"Z Yang","year":"2022","unstructured":"Yang Z, Zhao R, Gao W. The effects of curcumin on the biological behavior of colorectal cancer cells through the JAK\/STAT3 and RAS\/MAPK\/NF-\u03baB pathways. Investig Clin. 2022;63(4):353\u201362.","journal-title":"Investig Clin"},{"issue":"5","key":"14830_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052563","volume":"25","author":"E De Fazio","year":"2024","unstructured":"De Fazio E, Pittarello M, Gans A, Ghosh B, Slika H, Alimonti P, Tyler B. Intrinsic and microenvironmental drivers of glioblastoma invasion. Int J Mol Sci. 2024;25(5): 2563.","journal-title":"Int J Mol Sci"},{"key":"14830_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198231","volume":"292","author":"MA Romeo","year":"2021","unstructured":"Romeo MA, Montani MSG, Benedetti R, Giambelli L, D\u2019Aprile R, Gaeta A, Faggioni A, Cirone M. The cross-talk between STAT1\/STAT3 and ROS up-regulates PD-L1 and promotes the release of pro-inflammatory\/immune suppressive cytokines in primary monocytes infected by HHV-6B. Virus Res. 2021;292: 198231.","journal-title":"Virus Res"},{"key":"14830_CR101","doi-asserted-by":"crossref","unstructured":"Gill GS, Kharb S, Goyal G, Das P, Kurdia KC, Dhar R, Karmakar S. Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance. Immunopharmacol Immunotoxicol. 2025;47(4):485\u2013507.","DOI":"10.1080\/08923973.2025.2504906"},{"issue":"1","key":"14830_CR102","doi-asserted-by":"publisher","first-page":"20","DOI":"10.33696\/cancerimmunol.7.101","volume":"7","author":"JT Bruner","year":"2024","unstructured":"Bruner JT, Cozis JD, Marrah AJ, Mayberry TG, Cowan BB, Wakefield MR, Fang Y. Mechanisms and clinical implications of immune checkpoint inhibitors PD-1, CTLA-4, and TIM-3 in cancer. J Cancer Immunol. 2024;7(1):20\u20139.","journal-title":"J Cancer Immunol"},{"issue":"1","key":"14830_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6(1):1\u201324.","journal-title":"Mol Biomed"},{"issue":"1","key":"14830_CR104","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.tranon.2020.100918","volume":"14","author":"R Kato","year":"2021","unstructured":"Kato R, Jinnouchi N, Tuyukubo T, Ikarashi D, Matsuura T, Maekawa S, Kato Y, Kanehira M, Takata R, Ishida K. TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer. Transl Oncol. 2021;14(1):100918.","journal-title":"Transl Oncol"},{"issue":"3","key":"14830_CR105","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/biomedicines9030297","volume":"9","author":"DY Kang","year":"2021","unstructured":"Kang DY, Sp N, Lee J-M, Jang K-J. Antitumor effects of ursolic acid through mediating the inhibition of STAT3\/PD-L1 signaling in non-small cell lung cancer cells. Biomedicines. 2021;9(3):297.","journal-title":"Biomedicines"},{"key":"14830_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108429","volume":"215","author":"S Khalaf","year":"2020","unstructured":"Khalaf S, Toor SM, Murshed K, Kurer MA, Ahmed AA, Abu Nada M, Elkord E. Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients. Clin Immunol. 2020;215: 108429.","journal-title":"Clin Immunol"},{"key":"14830_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00315","volume":"8","author":"HT Marshall","year":"2018","unstructured":"Marshall HT, Djamgoz MB. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018;8: 315.","journal-title":"Front Oncol"},{"issue":"3","key":"14830_CR108","first-page":"1157","volume":"11","author":"S Cheng","year":"2018","unstructured":"Cheng S, Han F, Xu Y, Qu T, Ju Y. Expression of Tim-3 in breast cancer tissue promotes tumor progression. Int J Clin Exp Pathol. 2018;11(3):1157\u201366.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"14830_CR109","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3892\/mmr.2016.6065","volume":"15","author":"M Yu","year":"2017","unstructured":"Yu M, Lu B, Liu Y, Me Y, Wang L, Zhang P. Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression. Mol Med Rep. 2017;15(2):689\u201395.","journal-title":"Mol Med Rep"},{"key":"14830_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/genes11060703","author":"R Saleh","year":"2020","unstructured":"Saleh R, Toor SM, Al-Ali D, Sasidharan Nair V, Elkord E. Blockade of PD-1, PD-L1, and TIM-3 altered distinct immune- and cancer-related signaling pathways in the transcriptome of human breast cancer explants. Genes. 2020. https:\/\/doi.org\/10.3390\/genes11060703.","journal-title":"Genes"},{"issue":"1","key":"14830_CR111","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.addr.2009.11.026","volume":"62","author":"M de la Fuente","year":"2010","unstructured":"de la Fuente M, Ravi\u00f1a M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 2010;62(1):100\u201317.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"14830_CR112","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00428-023-03581-y","volume":"483","author":"C Poulios","year":"2023","unstructured":"Poulios C, Karagkiozaki V, Kapoukranidou D, Chakim Z, Zarampoukas T, Foroglou N, Logothetidis S. Bringing pathology to nanomedicine: a comparison of in vivo toxicity of polymeric nanoparticle carriers with and without chitosan coating. Virchows Arch. 2023;483(6):775\u201386.","journal-title":"Virchows Arch"},{"key":"14830_CR113","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijbiomac.2021.12.129","volume":"200","author":"I Dmour","year":"2022","unstructured":"Dmour I, Islam N. Recent advances on chitosan as an adjuvant for vaccine delivery. Int J Biol Macromol. 2022;200:498\u2013519.","journal-title":"Int J Biol Macromol"},{"key":"14830_CR114","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s13346-021-00968-9","volume":"11","author":"AS Cordeiro","year":"2021","unstructured":"Cordeiro AS, Farsakoglu Y, Crecente-Campo J, de la Fuente M, Gonz\u00e1lez SF, Alonso MJ. Carboxymethyl-\u03b2-glucan\/chitosan nanoparticles: new thermostable and efficient carriers for antigen delivery. Drug Deliv Transl Res. 2021;11:1689\u2013702.","journal-title":"Drug Deliv Transl Res"},{"issue":"8","key":"14830_CR115","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/vaccines11081333","volume":"11","author":"SC Gaglio","year":"2023","unstructured":"Gaglio SC, Perduca M, Zipeto D, Bardi G. Efficiency of chitosan nanocarriers in vaccinology for mucosal immunization. Vaccines. 2023;11(8):1333.","journal-title":"Vaccines"},{"issue":"3","key":"14830_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/md20030156","volume":"20","author":"MK Amin","year":"2022","unstructured":"Amin MK, Boateng JS. Enhancing stability and mucoadhesive properties of chitosan nanoparticles by surface modification with sodium alginate and polyethylene glycol for potential oral mucosa vaccine delivery. Mar Drugs. 2022;20(3): 156.","journal-title":"Mar Drugs"},{"issue":"1","key":"14830_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.111221","volume":"86","author":"H Pallathadka","year":"2025","unstructured":"Pallathadka H, Jabir M, Rasool KH, Hanumanthaiah M, Sharma N, Pramanik A, Rab SO, Jawad SF, Oghenemaro EF, Mustafa YF. siRNA-based therapy for overcoming drug resistance in human solid tumours; molecular and immunological approaches. Hum Immunol. 2025;86(1): 111221.","journal-title":"Hum Immunol"},{"issue":"5","key":"14830_CR118","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1517\/14728222.12.5.637","volume":"12","author":"C Huang","year":"2008","unstructured":"Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets. 2008;12(5):637\u201345.","journal-title":"Expert Opin Ther Targets"},{"key":"14830_CR119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40005-020-00504-w","volume":"51","author":"TM Kiio","year":"2021","unstructured":"Kiio TM, Park S. Physical properties of nanoparticles do matter. J Pharm Invest. 2021;51:35\u201351.","journal-title":"J Pharm Invest"},{"issue":"5","key":"14830_CR120","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/08820139.2021.1936011","volume":"51","author":"Y Liu","year":"2022","unstructured":"Liu Y, Duan Y, Yang N, Li B, Kong D. The TIM-3 rs10053538 polymorphism is associated with clinical prognosis of colorectal cancer. Immunol Invest. 2022;51(5):1302\u201312.","journal-title":"Immunol Invest"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14830-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:05:08Z","timestamp":1758809108000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14830-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14830"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14830-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1431"}}